Post-approval studies (Phase 4)UnknownNCT03677557
What this trial is testing
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
Who this might be right for
Primary Immunodeficiency DiseaseSecondary Immunodeficiency
Ottawa Hospital Research Institute 30